Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VIS649 in IgA Nephropathy
NCT04287985Phase 2Completed
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization
- Start
- Jul 2020
- Primary completion
- May 2023
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 15
01
Overview
A Phase 2 trial of sibeprenlimab in immunoglobulin A nephropathy (IgAN), sponsored by Otsuka Pharmaceutical Development & Commercialization. Started Jul 2020; status: completed.
02
Drugs
sibeprenlimab
03
Conditions
immunoglobulin A nephropathy (IgAN)
Beyond the preview
Go deeper on NCT04287985.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04287985.